Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Unity Biotechnology is a biopharmaceutical company focused on developing therapies that target cellular senescence to treat age-related diseases, particularly in ophthalmology and neurology. Its core programs include senolytic drugs like UBX1325 for eye diseases such as diabetic macular edema and age-related macular degeneration, aiming to eliminate senescent cells and reduce disease progression. The company leverages proprietary mechanisms to address fundamental aging processes, with a focus on clinical-stage development.
This description was generated via AI from an annual report. Updated about 1 year ago.